national perspective. SEER data collection was initiated in 1973. The first database, SEER 9, included 9 registries covering Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San FranciscoOakland, Seattle-Puget Sound, and Utah. SEER subsequently expanded its geographic range to enhance coverage of cancer incidence in minority populations to represent more accurately the general population. In 1992, SEER 13 was created with the addition of registries from Los Angeles, San JoseMonterrey, and rural Georgia, as well as the Alaska native tumor registry.
The most recent SEER 18 registry, established in 2001, includes additional data from the populations of greater California, greater Georgia, Kentucky, Louisiana, and New Jersey. The SEER 18 database reports data collected from 28% of the US population, offering the most current and accurate cancer incidence and national prevalence data from 1973 through 2014. 10, 11 The SEER 18 database was assessed for patients with malignancies diagnosed between 0 and 19 years of age. Using the "Primary Site-Labeled" search option, patients with malignancies of the "tonsillar fossa, tonsillar pillar, overlapping lesion of the tonsil, tonsil, lateral wall of the oropharynx, or overlapping lesion of the oropharynx," diagnosed between 1973 and 2013 were included. Patients were excluded if they were >19 years of age or if the specific oropharyngeal site of their tumor was not specified.
To generalize the data gathered from the SEER registry to the US pediatric population, incidence data were age adjusted and normalized to the 2000 US standard population census. A ratio of the number of pediatric tonsil cancer cases to the total number of patients aged 0-19 years in the SEER database was calculated for each year. The data were then weighted based on the proportion of patients in the SEER database compared with the 2000 US standard population. These annual incidence rates were averaged to obtain the final age adjusted incidence rate.
In parallel, a comprehensive chart review of all patients diagnosed with tonsillar asymmetry and/or tonsillar malignancies at our institution between January 2013 and January 2017 was also performed. Data collected included demographics, clinical presentation, examination findings, laboratory studies, imaging results, and histopathology. Tonsil size was standardized using the Brodsky scale. 12 In this classification system, tonsils are referenced relative to the oropharyngeal midline and graded on a 1-4 scale according to the fraction of the airway space the tonsil obstructs. 12 A tonsil size of 1+ corresponds with ≤25% oropharyngeal airway obstruction, 2+ means 50% of the airway space is obstructed, grade 3+ represents ≤75% obstruction, and grade 4+ tonsils completely obstruct the airway (Figure; available at www.jpeds.com). We defined "significant" tonsil asymmetry as tonsils that differed in size by ≥2 grades on the Brodsky scale. Volumetric data were calculated using the formula for ellipsoid volume (V = 4/3pabc) for patients who underwent bilateral tonsillectomy. A paired t test was used to compare tonsil volume between specimens taken from the same patient. Prominent cervical lymphadenopathy was defined as having ≥1 enlarged lymph node ≥1 cm within one of the cervical chains. Patients who underwent tonsillectomy because of concern regarding post-transplant lymphoproliferative disorder were excluded from this review.
The Boston Children's Hospital Institutional Review Board approved this retrospective study prior to data acquisition. Institutional Review Board guidelines were followed.
Results

SEER Data
Pediatric patients with a tonsillar malignancy (N = 138) were identified using the SEER 18 database. 11 The overall age adjusted incidence rate was 0.021/100 000 per year. There were 25 children <5 years of age, of which only 2 were <12 months of age. The majority of patients were in the 5-to 19-year-old age categories, with nearly equal distributions between 5-9, 10-14, and 15-19 years of age. Patients were primarily Caucasian (n = 112; 81.2%). There were more than twice as many males (n = 94; 68.1%) as females.
Non-Hodgkin lymphoma was the most common malignancy, constituting 87.0% of cases (n = 120) ( Table I) . Burkitt lymphoma was the most common subtype (n = 43; 31.1%), followed by diffuse large B-cell lymphoma (DLBCL; n = 37 [26.8%] ) and follicular lymphoma (n = 14; 10.1%). Rhabdomyosarcoma (n = 5; 3.62%), synovial sarcoma (n = 2; 1.44%), and plasmacytoma (n = 3; 2.2%) were comparatively rare SEER cohort diagnoses.
Among the 110 patients whose malignancies were unilateral, the incidence of malignancy was nearly equal between the right (n = 49; 35.5%) and left (n = 61; 44.2%) tonsils. In 16.0% of patients (n = 22), the primary malignancy was bilateral. Laterality was not specified for 6 cases.
Institutional Data
Data regarding the institutional tonsil malignancy cases are summarized in Table II . These data are consistent with the SEER findings in that 3 of the 5 children in our institutional cohort had Burkitt lymphoma; the other 2 children notably had acute lymphoblastic leukemia. Similar to the SEER cohort, 4 of the 5 children were male, all were Caucasian, and all were between the ages of 3 and 10 years. In 4 of the 5 children, their diagnosis was ascertained by tonsillectomy; tonsillectomy was deferred in 1 child because flow cytometry of a peripheral blood sample had already confirmed the diagnosis.
Of the 5 cases of tonsillar malignancy in the institutional cohort, 2 presented with obstructive sleep-disordered breathing manifestations. One of the 2 children who presented with obstructive symptoms also exhibited unilateral tonsillar asymmetry. Of the 4 patients who presented with unilateral tonsillar hypertrophy, 3 underwent bilateral tonsillectomy. ) in the contralateral tonsil. Prominent cervical lymphadenopathy was present in 4 of the 5 children on initial examination. Symptom duration before presentation ranged from 3 to 12 weeks. There was preoperative concern for malignancy in all of these patients.
There were 206 pediatric patients diagnosed with UTE in our institutional series who met the inclusion criteria; therefore, the incidence of tonsil malignancy in patients with UTE in our series was 1.9% (Table III) . Upon review of final pathology reports, there was no significant difference in tonsil volume between the enlarged tonsil and the contralateral specimen in patients with UTE who did not have tonsil malignancy (4.6 cm 3 vs 3.0 cm 3 ; P = .17). The Brodsky size difference between specimens taken from the same patient ranged from 0.5 to 1.5 in the UTE group without tonsil cancer. None of these patients were reported to have prominent cervical lymphadenopathy.
Discussion
Pediatric tonsil cancer is rare with the existent literature largely limited to small case series (Table III) . To expand on current knowledge, the SEER database was used to provide populationbased observational data. This comprehensive source of national cancer data includes demographics, cancer stage at diagnosis, primary site, and cancer subtype, allowing estimates of these measures on a national level. From a national perspective, 138 pediatric patients with tonsillar malignancy were identified in the 1973-2013 study period, translating to an age-adjusted population incidence rate of 0.021/100 000 pediatric patients per year. An evident male predominance is reflective of prior literature demonstrating male sex to be a risk factor for non-Hodgkin lymphoma, the most common tonsillar malignancy identified. 14 Analysis of the SEER database reveals non-Hodgkin lymphoma to be the most common tonsillar malignancy (n = 120; 87.0%), with Burkitt lymphoma being the most common nonHodgkin lymphoma subtype (n = 43; 31.2%). This observation reflects the prevalence of Burkitt lymphoma in the pediatric population at large, reported in 1 institutional review to represent approximately 60.7% of all pediatric non-Hodgkin lymphoma cases. 15 Burkitt lymphoma is considered an aggressive subtype in which translocation of the c-myc proto-oncogene is seen in the majority of cases, leading to rapid unregulated cell growth. 16 Treatment is intensive chemotherapy, based on risk stratification. [17] [18] [19] DLBCL is the second most common lymphoma subtype in the SEER cohort (n = 37; 26.8%). This is consistent with the reported prevalence of DLBCL as the second most common subtype of pediatric non-Hodgkin lymphoma, representing about 21.4% of pediatric non-Hodgkin lymphoma cases. 15 Although patients with DLBCL present typically with abdominal disease, adenotonsillar lymphatic tissue is the second most common primary site. 20 Similar to Burkitt lymphoma, DLBCL is considered an aggressive non-Hodgkin lymphoma subtype requiring intensive chemotherapy as treatment.
The third most common tonsillar malignancy in the SEER database is follicular lymphoma (10.1%). Follicular lymphoma represents only 1%-2% of all pediatric non-Hodgkin lymphomas with a notable 3 to 1 male to female predominance. 21, 22 Translocations of BCL2, characteristic of adult follicular lymphoma, are not frequently observed in children, perhaps accounting for the much more favorable prognosis of pediatric patients with follicular lymphoma. 23, 24 The vast majority of pediatric follicular lymphoma cases occur in the head and neck region and are detected at an early stage; in 2 separate series, 85% and 86% of pediatric patients with follicular lymphoma had either stage I or stage II disease. 25, 26 Rhabdomyosarcoma (n = 5; 3.6%) and plasmacytomas (n = 3; 2.2%) were comparatively rare tumors in the SEER cohort. The rhabdomyosarcoma neoplasms likely originated in the adjacent oropharyngeal musculature and involved the tonsils by direct extension. Multimodality therapy including chemotherapy, radiotherapy, and possibly additional surgery is typically required in such cases. 29, 30 Owing to local aggressiveness and a propensity to metastasize, surgical resection alone is rarely curative for tonsillar rhabdomyosarcoma. 29, 31 Extramedullary plasmacytoma is a soft tissue neoplasm of monoclonal plasma cells. Tonsillar plasmacytomas are extremely rare, even within the nonpediatric population. 32 Surgical resection alone, with or without radiotherapy, is sufficient to cure this disease. Effective local control can be achieved in ≤100% of cases of monoclonal extramedullary plasmacytoma; postoperative radiotherapy is recommended when complete resection is not possible. 33 It is noteworthy there were no cases of squamous cell carcinoma in the SEER cohort, because squamous cell carcinoma is the most common oropharyngeal malignancy in adults. The increasing prevalence of human papilloma virus-related cancers in otherwise healthy young men and women suggests future increases in the frequency of this human papilloma virus-associated tonsillar malignancy among younger patients may be anticipated. 34 Because the SEER data attest to the overall rarity of pediatric tonsillar malignancy, identifying clinical factors that may help to stratify patients with UTE is clearly necessary. This need is highlighted further by the fact tonsillar asymmetry is not an uncommon finding, manifesting in about 1.7% of the pediatric population. 35 The reported prevalence of tonsillar malignancy among patients with UTE in the literature ranges from 0% to 4%, and the overall rate of malignancy in patients of all ages who undergo tonsillectomy for UTE is 1.4% (Table III) . [4] [5] [6] [7] [8] [9] 13 The lack of a correlation between UTE and tonsillar malignancy is explained by the limited accuracy of the oropharyngeal examination in detecting truly asymmetric tonsils. In our series, there were 202 patients with UTE who underwent tonsillectomy and did not have tonsil malignancy based on final pathology review. The difference in Brodsky score ranged from 0.5 to 1.5 in these patients, with no significant difference in tonsil volume (P = .17), indicating the perceived asymmetry was due to other factors. Similarly, a prospective, controlled study comparing tonsil size and fossa depth in 47 patients with clinically asymmetrical tonsils compared with 43 patients with clinically symmetrical tonsils found no significant difference in 3-dimensional quantitative measurements of resected tonsil specimens. 7 The perceived tonsillar asymmetry was closely associated with a difference in the depth of the tonsillar fossa (P < .001). 7 Notably, the specific amount or degree of clinically observed asymmetry is typically not described in prior studies investigating UTE in the pediatric population. [4] [5] [6] The exception is the study outlined herein, in which all reported cases of asymmetry were described as "mild." 7 Although the majority of tonsil asymmetry is benign, most patients with tonsillar malignancy exhibit UTE. This finding was first reported in a small case series in which 6 of 7 patients with tonsillar malignancies had UTE. 4 A subsequent systematic review and meta-analysis confirmed this observation, documenting 52 of 71 patients (72.7%) with tonsillar lymphoma to have had clinically apparent asymmetry. 36 Similarly, a review of 6 pediatric patients with palatine tonsil lymphomas reported all to exhibit UTE. 37 Our institutional clinical experience is consistent with these results as 4 of 5 patients (80%) exhibited UTE.
It is important to note, however, that 16.0% of patients in the SEER database had bilateral malignancies. This finding was true of 1 case in our institutional cohort as well, a child who was eventually diagnosed with acute lymphoblastic leukemia. A previously published, prospective, controlled study reported no cases of malignancy in their "asymmetric tonsil" population, but 1 case of malignancy in a patient with dramatically enlarged tonsils bilaterally. 5 These findings suggest that clinical concern for malignancy should include patients with rapidly enlarging tonsils, whether in symmetrical bilateral or asymmetric unilateral fashion.
Because the 2 most common pediatric tonsillar malignancies are aggressive subtypes, it is critically important that cases of malignancy be diagnosed as early as possible so that chemotherapy may be initiated promptly. Our institutional cohort experience indicates that rapid tonsillar enlargement over ≤12 weeks, marked asymmetry, and prominent cervical lymphadenopathy are important signs of tonsillar malignancy. All cases of UTE of neoplastic origin on institutional review manifested relatively rapid tonsillar enlargement over a 3-to 12-week time course. The literature regarding pediatric tonsil cancer is limited given its rarity, but several case reports describe similar rapid tonsillar enlargement over a time course of days to weeks in pediatric patients who were later diagnosed with malignant UTE. [38] [39] [40] In our 4 cases of UTE secondary to tonsil malignancy, each had one 4+ tonsil, with all 4 of these patients demonstrating a difference in tonsil size score of at least two on the Brodsky scale. Volumetric analysis also confirmed a dramatic difference in size between affected and unaffected tonsils (20.3 versus 2.7 cm 3 ). This more significant degree of asymmetry lessens the ambiguity that true volumetric asymmetry is present.
Last, prominent cervical lymphadenopathy was present in 80% of our patients with tonsil malignancy. A prior systematic review likewise indicated cervical lymphadenopathy to be the third most common sign/symptom of tonsillar malignancy, documented in 30.3% of the patients reviewed. 41 There are several notable limitations to our study. The SEER database captures the incidence of cancer among only approximately 28% of the population. 10 Age-adjusted population data were necessary to calculate a national incidence rate; our estimates as a result may slightly overestimate or underestimate this rate. Some patients' tumors were categorized as "oropharynx, not otherwise specified" and were excluded from the analysis because there was no indication as to what oropharyngeal subsite was involved. It is, therefore, possible that some patients with tonsillar malignancies may have been excluded inadvertently. Finally, as with any retrospective study, the data obtained on institutional chart review were originally collected from a patient care rather than a study perspective. Any data incorrectly documented or omitted could alter our results.
In summary, tonsillar malignancy is the underlying etiology of only a very small percentage of pediatric UTE. In our practice, clinical suspicion is increased and tonsillectomy is warranted when there has been relatively rapid tonsillar enlargement within a several week time frame, particularly if the degree of asymmetry corresponds with a difference in score on the Brodsky scale of ≥2. Concurrent prominent cervical lymphadenopathy further increases the concern for malignancy. Tonsillectomy for excisional biopsy purposes should be performed conservatively, bearing in mind that a proactive diagnosis is important, because the majority of pediatric tonsillar malignancies are aggressive non-Hodgkin lymphoma subtypes. ■ THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 197 261.e1
